Postoperative radiotherapy in radically resected non-small cell lung cancer

被引:107
作者
Mayer, R
SmolleJuettner, FM
Szolar, D
Stuecklschweiger, GF
Quehenberger, F
Friehs, G
Hackl, A
机构
[1] GRAZ UNIV, SCH MED, DEPT THORAC & HYPERBAR SURG, GRAZ, AUSTRIA
[2] GRAZ UNIV, SCH MED, DEPT RADIODIAG, GRAZ, AUSTRIA
[3] GRAZ UNIV, SCH MED, DEPT MED INFORMAT STAT & DOCUMENTAT, GRAZ, AUSTRIA
关键词
lung cancer; postoperative radiotherapy; recurrence; surgery; survival;
D O I
10.1378/chest.112.4.954
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Purpose: To evaluate the value of adjuvant postoperative external-beam radiation (EBR) in patients with radically resected non-small cell lung cancer (NSCLC) pT1-3 pN0-2 compared to patients with resected NSCLC without adjuvant EBR. Materials and methods: In 155 patients (121 male, 34 female; mean age, 59 years) 105 lobectomies, 12 bilobectomies, and 38 pneumonectomies with radical lymph node dissection of the ipsilateral side were performed. Postoperative staging was done according to the TNM system and was as follows: pT1 (n=38), pT2 (n=89), pT3 (n=28), pN0 (n=39), pN1 (n=67) and pN2 (n=49). Histopathologic study revealed 68 squamous cell carcinomas, 53 adenocarcinomas, 21 large cell carcinomas, 6 adenosquamous cell carcinomas, and 7 bronchioloalveolar cell carcinomas. All patients were randomly assigned into two treatment groups: 72 patients with no further treatment (control group), and 83 patients (EBR group) with adjuvant postoperative EBR of the bronchial stump and mediastinum (50 to 56 Gy, 8 or 23 MV photons, 2 Gy/d, 5 d/wk) beginning 4 to 6 weeks after surgery. Results: The overall 5-year survival rate (median observation time, 43 months) of all patients was 24.1% (EBR group, 29.7%; control group, 20.4%; p>0.05, not significant). The relative risk of the EBR group was 0.85 with a two-sided confidence interval of 0.66 to 1.09. The overall 5-year recurrence-free survival was 20.6% (EBR, 27.1%; control group, 15.6%; p=0.07). The relative risk of the EBR group was 0.80 with a confidence interval of 0.63 to 1.01. The rate of local recurrences at the bronchial stump and/or mediastinum was significantly smaller in the EBR group (n=5) than in the control group (n=17) (p<0.01). Multivariate analysis (chi(2) test) demonstrated an independent influence of postoperative EBR on the incidence of local recurrences. The incidence of distant metastases was slightly but not significantly higher in patients without EBR (38 patients) compared to those who had EBR (32 patients). Conclusion: High-dose postoperative EBR to the mediastinum significantly reduces the risk of local recurrence at the bronchial stump and/or mediastinum. Age, sex, histological subtype, tumor size, surgical approach, or extent of lymph node involvement had no prognostic value-only postoperative EBR had an independent influence on the risk of local recurrence. The effect of postoperative EBR was on the verge of significance with respect to recurrence-free survival and showed the same tendency in overall survival, however with an attenuated relative risk.
引用
收藏
页码:954 / 959
页数:6
相关论文
共 24 条
[1]
[Anonymous], 1992, TNM classification of malignant tumors
[2]
INDUCTION CHEMOTHERAPY FOR NON-SMALL-CELL LUNG-CANCER WITH CLINICALLY EVIDENT MEDIASTINAL NODE METASTASES - THE ROLE OF POSTOPERATIVE RADIOTHERAPY [J].
ARMSTRONG, JG ;
MARTINI, N ;
KRIS, MG ;
HARRISON, LB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (03) :605-613
[3]
PROGRESS IN LUNG-CANCER - NON-OAT CELL (NON-SMALL CELL LUNG-CANCER) [J].
BEATTIE, EJ ;
RASKIN, NM .
JAPANESE JOURNAL OF SURGERY, 1987, 17 (05) :313-322
[4]
BASIS FOR NEW STRATEGIES IN POSTOPERATIVE RADIOTHERAPY OF BRONCHOGENIC-CARCINOMA [J].
CHOI, NCH ;
GRILLO, HC ;
GARDIELLO, M ;
SCANNELL, JG ;
WILKINS, EW .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1980, 6 (01) :31-35
[5]
COX JD, 1983, SEMIN ONCOL, V10, P81
[7]
POSTRESECTION IRRADIATION FOR PRIMARY LUNG-CANCER [J].
GREEN, N ;
KUROHARA, SS ;
GEORGE, FW ;
CREWS, QE .
RADIOLOGY, 1975, 116 (02) :405-407
[8]
RESULTS OF RADICAL RADIATION-THERAPY IN CLINICAL STAGE-I, TECHNICALLY OPERABLE NON-SMALL CELL LUNG-CANCER [J].
HAFFTY, BG ;
GOLDBERG, NB ;
GERSTLEY, J ;
FISCHER, DB ;
PESCHEL, RE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (01) :69-73
[9]
SURGICAL ADJUVANT THERAPY FOR STAGE-II AND STAGE-III ADENOCARCINOMA AND LARGE-CELL UNDIFFERENTIATED CARCINOMA [J].
HOLMES, EC ;
GAIL, M .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (05) :710-715
[10]
HOLMES EC, 1989, J SURG ONCOL, P26